** Shares in Genmab GMAB.CO fall around 4% after the Danish pharmaceutical company said it has agreed to buy Merus 2GH.F, MRUS.O for $8.0 billion in cash
** Genmab will pay $97 per share for Merus, the companies said, a 41% premium over Friday's closing price in New York trade
** The proposed acquisition aligns with Genmab's long‑term strategy and could accelerate its path to global biotech leadership, the group said in the statement
** "As these bispecific developers already share their research and development facilities under one roof, we see strong synergy in this acquisition," Kempen analysts write in a note
(Reporting by Agnieszka Olenska)
((Agnieszka.Olenska@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.